Overview
Pharmacokinetics of Fixed Dose Combination (FDC) Tablets of Linagliptin /Metformin
Status:
Completed
Completed
Trial end date:
2012-06-01
2012-06-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The aim of the trial is to assess the relative bioavailability of fixed dose combination tablets of linagliptin and metformin compared to the administration of two single tablets (linagliptin and metformin ) in Chinese subjects. The availability of a fixed dose combination tablet is expected to significantly enhance patients' compliance with antidiabetic treatment., in particular with concern to the frequent polypharmacy in diabetic patients.Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Boehringer IngelheimTreatments:
Linagliptin
Metformin
Criteria
Inclusion criteria:1. Healthy male and female subjects
Exclusion criteria:
1. Any relevant deviation from healthy conditions